Duration of Dual Antiplatelet Therapy After Coronary Artery Angioplasty with Stent Placement

Duration of Dual Antiplatelet Therapy Based on Stent Type

The American College of Cardiology recommends that for patients who have undergone coronary artery angioplasty with stent placement, Plavix (clopidogrel) should be continued for at least 12 months after drug-eluting stent (DES) implantation and for at least 1 month (ideally up to 12 months) after bare-metal stent (BMS) implantation 1, 2, 3
For bare-metal stents (BMS), the American Heart Association suggests clopidogrel 75 mg daily should be given for a minimum of 1 month and ideally up to 12 months if patients are not at high risk of bleeding 2, 3
For drug-eluting stents (DES), the American College of Cardiology recommends clopidogrel 75 mg daily should be given for at least 12 months 2, 3
For sirolimus-eluting stents, the guideline recommends a minimum of 3 months, ideally up to 12 months of clopidogrel therapy 4
For paclitaxel-eluting stents, the guideline recommends a minimum of 6 months, ideally up to 12 months of clopidogrel therapy 4

If the risk of morbidity from bleeding outweighs the anticipated benefit of continued P2Y12 inhibitor therapy, earlier discontinuation (less than 12 months) may be reasonable, according to the American College of Cardiology 2
For bare-metal stents with high bleeding risk, the minimum duration of clopidogrel therapy is 2 weeks 4, 3
For drug-eluting stents with high bleeding risk, the minimum duration of clopidogrel therapy is 3-6 months depending on stent type 3, 4

After completion of dual antiplatelet therapy, the American Heart Association recommends aspirin should be continued indefinitely at a dose of 75-162 mg daily 3
Lower-dose aspirin (81 mg daily) is reasonable for long-term therapy to reduce bleeding risk, according to the American College of Cardiology 2

Premature discontinuation of dual antiplatelet therapy significantly increases the risk of late stent thrombosis, which can lead to myocardial infarction and death, as stated by the American College of Cardiology 1

For patients requiring non-cardiac surgery, the American College of Cardiology recommends surgery should be deferred until patients have completed an appropriate course of dual antiplatelet therapy 1
If surgery cannot be delayed, aspirin should be continued if at all possible, according to the American College of Cardiology 1
The thienopyridine (clopidogrel) should be restarted as soon as possible after the procedure, as recommended by the American College of Cardiology 1
For patients on triple therapy (including warfarin), the American Heart Association suggests use of warfarin in conjunction with aspirin and clopidogrel increases bleeding risk and should be monitored closely 3
Consider a target INR of 2.0-2.5 with low-dose aspirin (75-81 mg) and standard clopidogrel (75 mg), as recommended by the American College of Cardiology 4

Discontinuing dual antiplatelet therapy prematurely is one of the most significant risk factors for stent thrombosis, particularly with drug-eluting stents, according to the American College of Cardiology 1
The risk of stent thrombosis extends beyond the traditional recommended durations, especially for drug-eluting stents, so clinicians should remain vigilant even beyond 365 days after DES placement, as stated by the American College of Cardiology 1
Patients should be counseled on the importance of compliance with dual antiplatelet therapy before stent implantation, according to the American College of Cardiology 2